✦ LIBER ✦

Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program

✍ Scribed by van den Eertwegh, Alfonsus J.M.; Karakiewicz, Pierre; Bavbek, Sevil; Rha, Sun Young; Bracarda, Sergio; Bahl, Amit; Ou, Yen-chuan; Kim, Dennis; Panneerselvam, Ashok; Anak, Oezlem; Grünwald, Viktor

Book ID: 123563175
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 104 KB
Volume: 81
Category: Article
ISSN: 0090-4295
DOI: 10.1016/j.urology.2012.09.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of gefitinib in chem

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program

✍ Govindan, Ramaswamy; Natale, Ronald; Wade, James; Herbst, Roy; Krebs, Annetta; R 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Safety and efficacy results of the advan

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

✍ Walter M. Stadler; Robert A. Figlin; David F. McDermott; Janice P. Dutcher; Jenn 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

## Abstract ## BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. ## METHODS: In this nonrandomized, open‐label expanded access program, 2504 patients from the United St

An expanded access program of erlotinib

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

✍ Tiseo, Marcello; Gridelli, Cesare; Cascinu, Stefano; Crinò, Lucio; Piantedosi, F 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 541 KB

7148 POSTER Hyperglycemia and Hyperchole

7148 POSTER Hyperglycemia and Hypercholesterolemia and Associated Outcomes of Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus in the Expanded-access Program REACT

✍ Bono, P.; Kim, D.; Panneerselvam, A.; Grünwald, V. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB

7137 POSTER Safety and Efficacy of Evero

7137 POSTER Safety and Efficacy of Everolimus in Patients With Non-clear Cell Renal Cell Carcinoma Refractory to VEGF-targeted Therapy – a Subgroup Analysis of the REACT Expanded-access Program

✍ Blank, C.; Bono, P.; Larkin, J.; Kim, D.; Panneerselvam, A.; Grünwald, V. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

7147 POSTER The REACT Expanded-access Pr

7147 POSTER The REACT Expanded-access Program of Everolimus in Patients With Metastatic Renal Cell Carcinoma Refractory to VEGF-targeted Therapy: Subgroup Analyses by Prior Therapy

✍ Larkin, J.; Blank, C.; Bono, P.; Kim, D.; Panneerselvam, A.; Grünwald, V. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB